Advent and GIC offer to buy drugmaker Sobi for around $8 billion - NewsBreak

Advent International and GIC offered to buy Swedish Orphan Biovitrum (STO: SOBI), a drugmaker primarily focused on rare diseases, for around $8 billion. Why it matters: It would be the largest-ever buyout of a Swedish company, and comes shortly after rival rare disease biotech Alexion was acquired for a whopping $39 billion by AstraZeneca.